{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T14:41:05Z","timestamp":1720449665108},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00393-019-0637-4","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T11:03:55Z","timestamp":1556795035000},"page":"422-428","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Komorbidit\u00e4ten \u2013 ihre Rolle im Treat-to-Target-Konzept f\u00fcr die rheumatoide Arthritis"],"prefix":"10.1007","volume":"78","author":[{"given":"K.","family":"Kr\u00fcger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kneitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"key":"637_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR et\u00a0al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3\u201315","journal-title":"Ann Rheum Dis"},{"key":"637_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00393-017-0294-4","volume":"77","author":"K Albrecht","year":"2018","unstructured":"Albrecht K, Luque Ramos A, Callhoff J et\u00a0al (2018) Ambulante Versorgung und Krankheitslast der rheumatoiden Arthritis. Eine Analyse von Abrechnungsdaten und einer Versichertenbefragung. Z\u00a0Rheumatol 77:102\u2013112","journal-title":"Z Rheumatol"},{"key":"637_CR3","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","volume":"108","author":"R Micha","year":"2011","unstructured":"Micha R, Imamura F, Wyler von Ballmoos M et al (2011) Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108:1362\u20131370","journal-title":"Am J Cardiol"},{"key":"637_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","volume":"76","author":"ASL Low","year":"2017","unstructured":"Low ASL, Symmons DPM, Lunt M et\u00a0al (2017) Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 76:654\u2013660","journal-title":"Ann Rheum Dis"},{"key":"637_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/rheumatology\/keq334","volume":"50","author":"H Radner","year":"2011","unstructured":"Radner H, Smolen JS, Aletaha D (2011) Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology 50:381\u2013388","journal-title":"Rheumatology"},{"key":"637_CR6","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1093\/rheumatology\/kev239","volume":"54","author":"H Radner","year":"2015","unstructured":"Radner H, Yoshida K, al Frits Met (2015) The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. Rheumatology 54:2076\u20132084","journal-title":"Rheumatology"},{"key":"637_CR7","volume-title":"Kerndokumentation. Deutsches Rheumaforschungszentrum","author":"Deutsches Rheumaforschungszentrum","year":"2016","unstructured":"Deutsches Rheumaforschungszentrum (2016) Kerndokumentation. Deutsches Rheumaforschungszentrum. Deutsches Rheumaforschungszentrum, Berlin (Daten noch unpubliziert)"},{"key":"637_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/acr.22642","volume":"68","author":"BR England","year":"2016","unstructured":"England BR, Sayles H, Michaud K et al (2016) Cause-specific mortality in male US veterans with rheumatoid arthritis. Arthritis Care Res 68:36\u201345","journal-title":"Arthritis Care Res"},{"key":"637_CR9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180668","author":"AL Ramos","year":"2019","unstructured":"Ramos AL, Redeker I, Hoffmann F et al (2019) Comorbidities in patients with rheumatoid arthritis and their association with patient-reported outcomes: results of claims data linked to questionnaire survey. J\u00a0Rheumatol. \n                    https:\/\/doi.org\/10.3899\/jrheum.180668","journal-title":"J Rheumatol"},{"key":"637_CR10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/annrheumdis-2014-206411","volume":"75","author":"E Myasoedova","year":"2016","unstructured":"Myasoedova E, Chandran A, Ilhan B et\u00a0al (2016) The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis 75:560\u2013565","journal-title":"Ann Rheum Dis"},{"key":"637_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-016-1077-z","volume":"18","author":"Y Meissner","year":"2016","unstructured":"Meissner Y, Zink A, Kekow J et\u00a0al (2016) Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Res Ther 18:183","journal-title":"Arthritis Res Ther"},{"key":"637_CR12","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/art.39098","volume":"67","author":"DH Solomon","year":"2015","unstructured":"Solomon DH, Reed GW, Kremer JM et\u00a0al (2015) Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheum 67:1449\u20131455","journal-title":"Arthritis Rheum"},{"key":"637_CR13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/annrheumdis-2014-206411","volume":"75","author":"E Myasoedova","year":"2016","unstructured":"Myasoedova E, Chandran A, Ilhan B et\u00a0al (2016) The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis 75:560\u2013565","journal-title":"Ann Rheum Dis"},{"key":"637_CR14","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T et al (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a\u00a0systematic review and meta-analysis. Ann Rheum Dis 74:480\u2013489","journal-title":"Ann Rheum Dis"},{"key":"637_CR15","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","volume":"108","author":"R Micha","year":"2011","unstructured":"Micha R, Imamura F, Wyler von Ballmoos M et al (2011) Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108:1362\u20131370","journal-title":"Am J Cardiol"},{"key":"637_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","volume":"77","author":"C Rempenault","year":"2018","unstructured":"Rempenault C, Combe B, Barnetche T et al (2018) Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a\u00a0systematic review and meta-analysis. Ann Rheum Dis 77:98\u2013103","journal-title":"Ann Rheum Dis"},{"key":"637_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2018.00177","author":"E Bartoloni","year":"2018","unstructured":"Bartoloni E, Alunno A, Valentini V et\u00a0al (2018) Targeting inflammation to prevent cardiovascular disease in chronic rheumatic diseases: myth or reality? Front Cardiovasc Med. \n                    https:\/\/doi.org\/10.3389\/fcvm.2018.00177","journal-title":"Front. Cardiovasc. Med."},{"key":"637_CR18","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1002\/art.22809","volume":"56","author":"WG Dixon","year":"2007","unstructured":"Dixon WG, Watson KD, Lunt M et al (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56:2905\u20132912","journal-title":"Arthritis Rheum"},{"key":"637_CR19","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3899\/jrheum.170926","volume":"45","author":"Y Jin","year":"2018","unstructured":"Jin Y, Kang EH, Brill G et\u00a0al (2018) Cardiovascular (CV) risk after initiation of\u00a0Abatacept\u00a0versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease. J\u00a0Rheumatol 45:1240\u20131248","journal-title":"J Rheumatol"},{"key":"637_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.semarthrit.2018.03.012","volume":"48","author":"SC Kim","year":"2018","unstructured":"Kim SC, Solomon DH, Rogers JR et\u00a0al (2018) No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: a\u00a0multidatabase cohort study. Semin Arthritis Rheum 48:399\u2013405","journal-title":"Semin Arthritis Rheum"},{"key":"637_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-018-0584-5","author":"K Kr\u00fcger","year":"2019","unstructured":"Kr\u00fcger K, N\u00fc\u00dflein H (2019) Kardiovaskul\u00e4re Komorbidit\u00e4ten bei rheumatoider Arthritis. Z\u00a0Rheumatol. \n                    https:\/\/doi.org\/10.1007\/s00393-018-0584-5","journal-title":"Z Rheumatol"},{"key":"637_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","volume":"77","author":"CS Crowson","year":"2018","unstructured":"Crowson CS, Rollefstad S, Ikdahl E et\u00a0al (2018) Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 77:48\u201354","journal-title":"Ann Rheum Dis"},{"key":"637_CR23","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1136\/annrheumdis-2013-203682","volume":"72","author":"J Primdahl","year":"2013","unstructured":"Primdahl J, Clausen J, H\u00f8rslev-Petersen K (2013) Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations. Ann Rheum Dis 72:1771\u20131776","journal-title":"Ann Rheum Dis"},{"key":"637_CR24","first-page":"1472","volume":"56","author":"IAM Van den Oever","year":"2017","unstructured":"Van den Oever IAM, Heslinga M, Griep EN et\u00a0al (2017) Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the implementation of cardiovascular risk management in rheumatoid arthritis project. Baillieres Clin Rheumatol 56:1472\u20131478","journal-title":"Baillieres Clin Rheumatol"},{"key":"637_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00296-018-4183-1","volume":"39","author":"JJCS Veldhuijzen van Zanten","year":"2019","unstructured":"Veldhuijzen van Zanten JJCS, Sandoo A, Metsios GS et al (2019) Comparison of the effects of exercise and anti-TNF treatment on cardiovascular health in rheumatoid arthritis: results from two controlled trials. Rheumatol Int 39:219\u2013225","journal-title":"Rheumatol Int"},{"key":"637_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10067-017-3966-1","volume":"37","author":"S Wang","year":"2018","unstructured":"Wang S, He Q, Shuai Z (2018) Risk of serious infections in biological treatment of patients with\u00a0ankylosing spondylitis\u00a0and non-radiographic axial spondyloarthritis: a\u00a0meta-analysis. Clin Rheumatol 37:439\u2013450","journal-title":"Clin Rheumatol"},{"key":"637_CR27","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O\u2019Fallon WM, Gabriel SE (2002) Frequency of\u00a0infection\u00a0in patients with\u00a0rheumatoid arthritis\u00a0compared with controls: a\u00a0population-based study. Arthritis Rheum 46:2287\u20132293","journal-title":"Arthritis Rheum"},{"key":"637_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, H\u00f6glund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K, European Vasculitis Study Group. (2011) Long-term patient survival in ANCA-associated\u00a0vasculitis. Ann Rheum Dis 70:488\u2013494","journal-title":"Ann Rheum Dis"},{"key":"637_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, European Vasculitis Study Group (2010) Rituximab versus cyclophosphamide in ANCA-associated renal\u00a0vasculitis. N\u00a0Engl J Med 363:211\u2013220","journal-title":"N Engl J Med"},{"key":"637_CR30","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/art.39070","volume":"67","author":"CH Feldman","year":"2015","unstructured":"Feldman CH, Hiraki LT, Winkelmayer WC et\u00a0al (2015) Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol 67:1577\u20131585","journal-title":"Arthritis Rheumatol"},{"key":"637_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","volume":"77","author":"D Khanna","year":"2018","unstructured":"Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, M\u00fcller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE (2018) Safety and efficacy of subcutaneous\u00a0tocilizumab\u00a0in systemic sclerosis: results from the open-label period of a\u00a0phase II randomised controlled trial (faSScinate). Ann Rheum Dis 77:212\u2013220","journal-title":"Ann Rheum Dis"},{"key":"637_CR32","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1159\/000338145","volume":"30","author":"A Kohn","year":"2012","unstructured":"Kohn A, Meddi P (2012) How to manage IBD in patients with infections or malignancies? Dig Dis 30:420\u2013424","journal-title":"Dig Dis"},{"key":"637_CR33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/annrheumdis-2017-212588","volume":"77","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Baddley JW (2018) Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question. Ann Rheum Dis 77:631\u2013633","journal-title":"Ann Rheum Dis"},{"key":"637_CR34","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2016","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barber\u00e0 J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC, ZOE-50 Study Group. (2016) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N\u00a0Engl J Med 372:2087\u20132096","journal-title":"N Engl J Med"},{"key":"637_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key394","author":"S Wijetilleka","year":"2019","unstructured":"Wijetilleka S, Jayne DR, Mukhtyar C et\u00a0al (2019) Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. Rheumatology. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/key394","journal-title":"Rheumatology"},{"key":"637_CR36","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S et al (2015) Risk\u00a0of serious\u00a0infection\u00a0in biological treatment of patients with\u00a0rheumatoid arthritis: a\u00a0systematic review and meta-analysis. Lancet 386:258\u2013265","journal-title":"Lancet"},{"key":"637_CR37","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1136\/annrheumdis-2011-200702","volume":"71","author":"WG Dixon","year":"2012","unstructured":"Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, Sylvestre MP (2012) Immediate and delayed impact of oral glucocorticoid therapy on\u00a0risk\u00a0of serious\u00a0infection\u00a0in older patients with\u00a0rheumatoid arthritis: a\u00a0nested case-control analysis. Ann Rheum Dis 71:1128\u20131133","journal-title":"Ann Rheum Dis"},{"key":"637_CR38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"27","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S et al (2017) Trial of\u00a0tocilizumab\u00a0in\u00a0giant-cell\u00a0arteritis. N\u00a0Engl J Med 27:317\u2013328","journal-title":"N Engl J Med"},{"key":"637_CR39","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/rheumatology\/kex528","volume":"57","author":"F Matcham","year":"2018","unstructured":"Matcham F, Davies R, Hotopf M et\u00a0al (2018) The relationship between depression and biologic treatment response in rheumatoid arthritis: An analysis of the British Society for Rheumatology Biologics Register. Rheumatology 57:835\u2013843","journal-title":"Rheumatology"},{"key":"637_CR40","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3899\/jrheum.131171","volume":"41","author":"N Inanc","year":"2014","unstructured":"Inanc N, Yilmaz-Oner S, Can M et al (2014) The role of depression, anxiety, fatigue, and fibromyalgia on the evaluation of the remission status in patients with rheumatoid arthritis. J\u00a0Rheumatol 41:1755\u20131760","journal-title":"J Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-0637-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-019-0637-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-0637-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T23:53:18Z","timestamp":1588290798000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-019-0637-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["637"],"URL":"https:\/\/doi.org\/10.1007\/s00393-019-0637-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]},"assertion":[{"value":"2 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Kr\u00fcger: Honorare f\u00fcr Fortbildung\/Beratung von folgenden Firmen: AbbVie, BMS, Biogen, Hexal, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, Roche, Sanofi, UCB. C.\u00a0Kneitz: Honorare f\u00fcr Fortbildung\/Beratung von folgenden Firmen: AbbVie, Berlin Chemie, BMS, Celgene, Chugai, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}